newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Reports Second Quarter 2021 Financial Results

- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021- - Announced two additional LILRB family targets as potential future development candidates